Consistently, CpG-2722/CDN adjuvanted vaccines generated higher antibody titers for interfering with the RBD protein/ACE2 interaction and inhibition of viral infection than that generated by the vaccine adjuvanted with CpG-2722 alone (Figure 1C and D). Here, ACE2 is linked to viral infectious disease.